China National Pharmaceutical Group Co Ltd (Sinopharm) has fostered national innovative enterprises across the country, as well as top-notch national strategic sci-tech innovation platforms, including national key laboratories, national engineering technology research centers, national engineering laboratories, biosafety level 3 (BSL-3) laboratories and production bases. 

Over the years, Sinopharm has won more than 70 awards, including the State Scientific and Technological Progress Award. It has led or participated in the formulation of more than 3,500 national technical standards, obtained more than 3,490 patents and received over 5,000 drug production approvals. 

Sinopharm serves as the pillar of the national vaccine chain and is the source of original technologies for central Stated-owned enterprises. Over 40 products of Sinopharm have received certificates from the World Health Organization (WHO), the US Food and Drug Administration (FDA) and the European Union (EU), with some of them having received WHO Emergency Use Listing (EUL).